55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules

Key Takeaways Explain This Topic AI

Primary hypothyroidism is characterized biochemically by an elevated serum TSH and low free T4, overwhelmingly caused by Hashimoto thyroiditis (anti-TPO and anti-thyroglobulin antibodies); standard weight-based replacement with levothyroxine is 1.6 mcg/kg/day in young healthy adults, whereas elderly patients or those with coronary artery disease require a conservative starting dose of 25 to 50 mcg/day to prevent precipitating myocardial ischemia or dysrhythmias.

Levothyroxine must be ingested on an empty stomach with plain water 30 to 60 minutes before breakfast or at bedtime (3 to 4 hours post-dinner), separated by at least 4 hours from calcium carbonate, ferrous sulfate, proton pump inhibitors, and sucralfate; upon confirmed pregnancy, maternal levothyroxine requirements increase by 25% to 30% immediately, necessitating an empiric dose increase of two additional tablets per week to maintain a TSH target <2.5 mIU/L.

Subclinical hypothyroidism (elevated TSH with normal free T4) warrants levothyroxine therapy when TSH is >=10.0 mIU/L (proven to reduce cardiovascular events and heart failure progression), in women who are pregnant or seeking pregnancy, or in the presence of severe hypothyroid symptoms or positive anti-TPO antibodies with TSH above normal to 9.9 mIU/L.

Hyperthyroidism etiology dictates management: Graves disease (TRAb/TSI positive, diffuse homogeneous RAIU) is treated with methimazole (preferred; monitor CBC for agranulocytosis) or PTU (strictly indicated in the first trimester of pregnancy and thyroid storm due to severe hepatotoxicity risks), radioactive iodine ablation, or thyroidectomy; painful subacute (De Quervain) thyroiditis is post-viral, self-limiting with low RAIU and elevated ESR/CRP, and is managed with NSAIDs and beta-blockers rather than antithyroid medications.

Evaluation of thyroid nodules begins with serum TSH and dedicated neck ultrasound: hot nodules (suppressed TSH with focal hyperfunctioning uptake on radionuclide scintigraphy) are virtually never malignant and do not undergo FNA, whereas cold or euthyroid nodules are risk-stratified by ACR TI-RADS (TR3 >=2.5 cm, TR4 >=1.5 cm, TR5 solid hypoechoic with microcalcifications/taller-than-wide >=1.0 cm) and Bethesda cytopathology (Bethesda II benign, Bethesda VI malignant, predominantly papillary thyroid cancer with psammoma bodies).

Last updated: September 2026

Primary Hypothyroidism: Etiology, Clinical Manifestations & Pharmacotherapy

Hypothyroidism is a common clinical disorder characterized by systemic deficiency of thyroid hormones, leading to generalized hypometabolism. Primary hypothyroidism accounts for >95% of cases and results from direct intrinsic thyroid gland failure, reflected biochemically by an elevated serum thyroid-stimulating hormone (TSH) and a low serum free thyroxine (free T4).

Etiologies of Primary Hypothyroidism

Hashimoto Thyroiditis (Chronic Autoimmune Thyroiditis) :

The most common cause of hypothyroidism in iodine-sufficient geographic areas (including North America).

Autoimmune destruction mediated by CD4+ and CD8+ T-lymphocytes and autoantibodies targeting thyroid tissue: anti-thyroperoxidase (anti-TPO) antibodies (present in 90% to 95% of patients) and anti-thyroglobulin (anti-Tg) antibodies (present in 60% to 80%).

Histopathology demonstrates extensive lymphocytic infiltration, germinal centers, destruction of thyroid follicles, and characteristic metaplastic Hurthle (Askanazy) cells with prominent eosinophilic granular cytoplasm.

Carries a markedly increased long-term risk of primary thyroid lymphoma (typically non-Hodgkin B-cell lymphoma), which should be suspected if a patient with longstanding Hashimoto disease develops a rapidly enlarging, firm neck mass.

Iatrogenic & Post-Ablative :

Radioactive iodine ( 131 I ^{131}\text{I} 131 I ) therapy for Graves disease or toxic goiter (predictable development of permanent hypothyroidism within 3 to 12 months).

Total or subtotal surgical thyroidectomy.

External beam neck irradiation for Hodgkin lymphoma or head and neck malignancies.

Iodine Deficiency & Iodine Excess :

Iodine Deficiency : The most common cause of hypothyroidism and endemic goiter worldwide.

Iodine Excess (The Wolff-Chaikoff Effect) : High intrathyroidal concentrations of inorganic iodide paradoxically inhibit thyroid peroxidase and organification of iodide. In healthy individuals, the gland "escapes" from this inhibition within several days; however, in patients with underlying autoimmune thyroiditis, the escape mechanism fails, leading to persistent iodine-induced hypothyroidism. Common sources include amiodarone (each 200 mg tablet contains 75 mg of iodine, releasing 7 mg of free inorganic iodine daily) and iodinated intravenous radiocontrast media.

Pharmacologic Inhibitors :

Lithium : Accumulates in the thyroid gland, inhibiting thyroid hormone synthesis and release (hypothyroidism develops in 15% to 20% of chronic users).

Immune Checkpoint Inhibitors (anti-PD-1 [pembrolizumab, nivolumab], anti-CTLA-4 [ipilimumab]): Induce destructive autoimmune thyroiditis, often presenting with a brief transient thyrotoxic phase followed by permanent primary hypothyroidism.

Tyrosine Kinase Inhibitors (sunitinib, sorafenib): Cause thyroid capillary regression and ischemic follicular atrophy.

Clinical Manifestations

Because thyroid hormones regulate cellular metabolic rate throughout all tissues, clinical features reflect generalized slowing of organ systems: CLINICAL MANIFESTATIONS OF HYPOTHYROIDISM

• System Signs and Symptoms
• ═════════════════════════════════════════════════════════════════════════════
• Constitutional Fatigue, lethargy, cold intolerance, unexplained modest weight gain
• (typically 5-10 lbs, predominantly fluid retention), hypothermia

• Dermatologic Dry, coarse, scaly skin; brittle hair and nails; diffuse alopecia;
• loss of outer third of the eyebrows (madarosis); non-pitting
• myxedematous puffiness (periorbital and pretibial glycosaminoglycan deposition)

• Neuromuscular Delayed relaxation phase of deep tendon reflexes ("hung-up" reflex,
• Woltman sign, most easily recognized at Achilles tendon);
• proximal muscle weakness, myalgias, carpal tunnel syndrome

Gastrointestinal Severe constipation, decreased peristalsis, paralytic ileus

• Cardiovascular Bradycardia, narrowed pulse pressure, diastolic hypertension,
• pericardial effusion, decreased cardiac contractility

• Reproductive / Endo Menorrhagia, oligomenorrhea, anovulation, infertility;
• hyperprolactinemia and galactorrhea (compensatory high TRH directly
• stimulates pituitary lactotrophs to secrete prolactin)

• Metabolic / Labs Hyponatremia (impaired free water clearance secondary to elevated ADH),
• normocytic or macrocytic anemia, elevated LDL-cholesterol, elevated CK
• ═════════════════════════════════════════════════════════════════════════════
• Levothyroxine Pharmacotherapy & Administration Counseling

Synthetic levothyroxine ( T 4 T_4 T 4 ​ ) is the sole first-line replacement therapy of choice. Triiodothyronine ( T 3 T_3 T 3 ​ , liothyronine) and desiccated thyroid extract (Armour Thyroid) are not recommended for routine initial therapy due to short half-lives, fluctuating plasma concentrations, supraphysiologic T 3 T_3 T 3 ​ spikes, and heightened cardiovascular risk. LEVOTHYROXINE INITIAL DOSING STRATIFICATION

• Patient Population Recommended Initial Levothyroxine Dosing Strategy
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• Young (< 50-60 years), Healthy, Full weight-based replacement: ~1.6 mcg/kg/day
• No Coronary Disease (calculated using ideal body weight; typically 75-125 mcg/day)

• Older Adults (>= 50-60 years) Conservative starting dose: 25 to 50 mcg/day;
• WITHOUT Known CAD titrate upward by 12.5 to 25 mcg increments every 6 to 8 weeks

• Documented Coronary Artery Disease "Start low and go slow": 12.5 to 25 mcg/day;
• or Severe Frailty / Heart Failure titrate by 12.5 mcg every 6 to 8 weeks under close clinical monitoring
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• *Rationale for Elderly/CAD Caution: Full replacement abruptly increases myocardial oxygen demand (MVO2),

which can precipitate severe angina, acute myocardial infarction, or fatal tachyarrhythmias.

Crucial Patient Administration Counseling :

Empty Stomach Requirement : Levothyroxine absorption occurs primarily in the duodenum and jejunum, requiring gastric acidity for optimal dissolution (oral bioavailability 60% to 80%). The tablet must be taken with a full glass of plain water at least 30 to 60 minutes before breakfast , or alternatively at bedtime at least 3 to 4 hours after the final evening meal .

The 4-Hour Separation Rule : Levothyroxine binds avidly to polyvalent cations and compounds that alter gastric pH. Patients must separate levothyroxine ingestion by at least 4 hours from:

• Calcium carbonate and calcium citrate supplements
• Ferrous sulfate and iron-containing multivitamins
• Aluminum- or magnesium-containing antacids and sucralfate
• Proton pump inhibitors (omeprazole, pantoprazole) and H2-receptor antagonists
• Bile acid sequestrants (cholestyramine, colesevelam)
• Dietary espresso/coffee, soy products, and high-fiber foods

Therapeutic Monitoring Protocol :

Synthetic T 4 T_4 T 4 ​ possesses an elimination half-life of 7 days , requiring approximately 6 weeks (5 half-lives) to reach steady-state serum concentrations.

Measure serum TSH 6 to 8 weeks after initiating therapy or after any dosage adjustment.

Once the target serum TSH is achieved within the normal laboratory reference range (typically 0.5 to 4.5 mIU/L), monitoring can be spaced to every 6 to 12 months , or sooner if the patient experiences significant weight changes, starts interfering medications, or becomes pregnant.

Pregnancy Considerations & Dosing Protocol :

Thyroid hormone is indispensable for early fetal neurodevelopment. Prior to 10 to 12 weeks gestation, the fetus is entirely dependent on transplacental transfer of maternal T 4 T_4 T 4 ​ .

Estrogen surges during early pregnancy double circulating thyroxine-binding globulin (TBG) , and human chorionic gonadotropin (hCG) weakly stimulates the TSH receptor, leading to a mandatory 25% to 50% increase in maternal thyroid hormone requirements .

Pre-Conception Counseling : Women on levothyroxine contemplating pregnancy should optimize preconception TSH to < 2.5 mIU/L .

Immediate Pregnancy Dose Escalation : As soon as pregnancy is confirmed (e.g., positive home pregnancy test), the patient should immediately increase her levothyroxine dose by approximately 25% to 30% without waiting for laboratory confirmation. A standard practical instruction is to take two additional tablets per week (e.g., taking a double dose on two non-consecutive days, such as Monday and Friday).

Trimester Monitoring : Recheck serum TSH every 4 weeks throughout the first half of pregnancy (up to 20 weeks gestation), and at least once between 26 and 32 weeks. The target TSH during pregnancy is <2.5 mIU/L (or within lower trimester-specific reference ranges). Following delivery, maternal levothyroxine is immediately reduced to the patient's pre-pregnancy baseline dose, with TSH checked at 6 weeks postpartum.

Subclinical Hypothyroidism: Diagnosis & Evidence-Based Treatment Indications

Subclinical hypothyroidism is a biochemical diagnosis defined by an elevated serum TSH level in the presence of a normal serum free T4 level . It is prevalent in 4% to 10% of the general adult population, with higher rates observed in older women. BIOCHEMICAL SPECTRUM OF THYROID FUNCTION TESTS

• Clinical State Serum TSH Level Serum Free T4 Level
• ═════════════════════════════════════════════════════════════════════════════
• Overt Primary Hypothyroidism Elevated (> 4.5 mIU/L) Low (< normal range)
• Subclinical Hypothyroidism Elevated (> 4.5 mIU/L) Normal (within range)
• Euthyroid Baseline Normal (0.5 - 4.5 mIU/L) Normal (within range)
• Subclinical Hyperthyroidism Suppressed (< 0.4 mIU/L) Normal (within range)
• Overt Hyperthyroidism Suppressed (< 0.1 mIU/L) Elevated (> normal range)
• ═════════════════════════════════════════════════════════════════════════════
• Clinical Rule: Confirm Before Treating

A single mildly elevated TSH reading must never trigger automatic lifelong pharmacotherapy. Up to 30% to 50% of mildly elevated TSH values spontaneously normalize on repeat testing. Transient elevations frequently occur during recovery from non-thyroidal illness (euthyroid sick syndrome) or following viral destructive thyroiditis. Clinicians must re-evaluate serum TSH and free T4 in 6 to 12 weeks before establishing the diagnosis of persistent subclinical hypothyroidism.

Indications for Levothyroxine Treatment in Subclinical Hypothyroidism

Initiating levothyroxine in subclinical hypothyroidism remains nuanced. The decision is driven by the absolute degree of TSH elevation, cardiovascular risk factors, reproductive plans, and symptoms:

Marked Elevation: Serum TSH >= 10.0 mIU/L :

Definitive Treatment Indication : Guidelines from the American Thyroid Association (ATA) and American Association of Clinical Endocrinology (AACE) universally recommend levothyroxine replacement for all patients with confirmed TSH >=10.0 mIU/L, regardless of symptoms.

Clinical Rationale : A TSH >=10.0 mIU/L is associated with a significantly increased risk of adverse cardiovascular outcomes, including accelerated atherosclerosis, ischemic heart disease events, diastolic dysfunction, and a 40% to 50% higher risk of heart failure hospitalization. In addition, the annual rate of progression from subclinical to overt hypothyroidism exceeds 5% per year in this cohort.

Pregnancy or Active Infertility Workup :

Definitive Treatment Indication : Any pregnant woman with subclinical hypothyroidism (TSH >2.5 mIU/L with normal free T4) or any woman undergoing assisted reproductive technology (ART) must be treated with levothyroxine to reduce risks of spontaneous abortion, preeclampsia, placental abruption, and adverse fetal neurocognitive development.

Mild Elevation: Serum TSH > Upper Limit of Normal to 9.9 mIU/L :

Treatment is selective and individualized based on the following specific clinical criteria:

Severe or Classic Hypothyroid Symptoms : A therapeutic trial of low-dose levothyroxine (25 to 50 mcg/day) for 3 to 6 months is reasonable; if symptoms do not objectively improve, the medication should be discontinued.

Presence of Goiter : To prevent further thyromegaly.

Positive Anti-Thyroperoxidase (Anti-TPO) Antibodies : Indicates underlying Hashimoto thyroiditis, conferring a high annual rate of progression to overt disease (~4.3% per year vs. 2.6% in antibody-negative patients).

Younger Age (< 65-70 years) with high cardiovascular risk profiles or hyperlipidemia.

The Elderly Paradox (Patients Aged >= 65-70 Years) :

In older adults, serum TSH physiologically shifts upward with aging. Landmark randomized controlled trials (such as the TRUST trial ) demonstrated that levothyroxine treatment for subclinical hypothyroidism in adults aged 65 years and older provided no symptomatic benefit, no improvement in cognitive function, and no reduction in fatigue or cardiovascular events .

Furthermore, treatment in this demographic introduces substantial risks of iatrogenic thyrotoxicosis, precipitating atrial fibrillation, osteoporosis, and fragility fractures .

Recommendation : For patients aged >=65 to 70 years with mild subclinical hypothyroidism (TSH < 10.0 mIU/L), routine levothyroxine therapy is NOT recommended ; watchful waiting with serial thyroid function tests every 6 to 12 months is the standard of care.

Thyrotoxicosis & Hyperthyroidism: Differential Diagnosis & Evidence-Based Management

Thyrotoxicosis describes the clinical hypermetabolic syndrome resulting from inappropriately high circulating concentrations of free thyroid hormones ( T 4 T_4 T 4 ​ and/or T 3 T_3 T 3 ​ ). Hyperthyroidism is a subset of thyrotoxicosis caused specifically by de novo excess thyroid hormone synthesis by the thyroid gland itself.

Diagnostic Differentiation of Thyrotoxicosis

Biochemical screening begins with serum TSH, which is suppressed (<0.01-0.1 mIU/L), accompanied by elevated free T4 and/or free T3. The definitive diagnostic tool to differentiate etiologies is the 24-Hour Radioactive Iodine Uptake and Scan (RAIU) : DIAGNOSTIC DIFFERENTIATION OF THYROTOXICOSIS

• Condition Pathophysiology Exam Findings RAIU Pattern / Labs
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Graves Disease Autoimmune TSI / TRAb Diffuse, non-tender Diffuse, homogeneous,
• stimulates TSH receptors goiter with bruit; elevated uptake (50-80%);
• proptosis; pretibial positive TSI / TRAb
• myxedema (dermopathy)

• Toxic Multinodular Autonomous hyperfunctioning Large, asymmetric, Patchy, heterogeneous
• Goiter (Plummer) follicles (older adults) nodular goiter; no uptake with areas of hot
• eye/skin signs and suppressed tissue

• Toxic Adenoma Single autonomous somatic Solitary palpable nodule; Focal hot nodule with
• TSH receptor mutation remainder normal complete suppression of
• the rest of the gland

• Subacute (De Quervain) Post-viral inflammatory Exquisitely tender, Low / near-zero RAIU (<1%);
• Thyroiditis follicular disruption painful goiter radiating markedly elevated ESR/CRP;
• releasing stored hormone to jaw; fever, malaise low thyroglobulin

• Subacute Lymphocytic Autoimmune destruction Painless, non-tender, Low / near-zero RAIU (<1%);
• (Silent / Postpartum) (within 1 yr of delivery) normal or firm goiter positive anti-TPO (50-80%)

• Factitious Exogenous thyroid hormone Thyroid gland is small, Low / near-zero RAIU (<1%);
• Thyrotoxicosis ingestion (surreptitious) non-palpable, or atrophic low serum thyroglobulin
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Management Modalities for Graves Disease

Graves disease is the most common cause of hyperthyroidism (60% to 80% of cases), characterized by autoantibodies against the TSH receptor (thyroid-stimulating immunoglobulins, TSI). Three definitive therapeutic options exist, paired with initial symptomatic control:

Symptomatic Adrenergic Blockade (Beta-Blockers) :

Propranolol (20 to 40 mg PO three to four times daily) or Atenolol (25 to 50 mg daily) should be initiated immediately in all symptomatic patients with moderate-to-severe thyrotoxicosis to control palpitations, tachycardia, tremors, and heat intolerance.

High-dose propranolol (>=160 mg/day) provides the added pharmacologic benefit of weakly inhibiting peripheral 5'-monodeiodinase conversion of T 4 T_4 T 4 ​ to active T 3 T_3 T 3 ​ .

Antithyroid Drugs (Thionamides: Methimazole vs. PTU) :

Mechanism of Action : Both agents act as competitive inhibitors of thyroid peroxidase (TPO) , blocking the organification of iodide and the coupling of iodotyrosines, thereby halting de novo thyroid hormone synthesis.

Methimazole (MMI) : The preferred first-line antithyroid drug for virtually all non-pregnant adults and children due to once-daily dosing (5 to 30 mg daily), rapid efficacy, and a substantially lower risk of fatal hepatotoxicity compared to PTU.

Propylthiouracil (PTU) : Administered in divided doses (100 to 150 mg PO three times daily). In addition to inhibiting TPO, PTU partially inhibits peripheral conversion of T 4 T_4 T 4 ​ to T 3 T_3 T 3 ​ .

Indications for PTU Over Methimazole :

First Trimester of Pregnancy (Weeks 1 to 12) : Methimazole is a recognized teratogen associated with aplasia cutis congenita (congenital scalp defects) and choanal or esophageal atresia . PTU carries lower embryopathy risks and is the mandatory drug of choice in the first trimester. At the start of the second trimester (week 13), patients are routinely switched to methimazole to avoid PTU-induced maternal hepatotoxicity.

Thyroid Storm : PTU's ability to acutely block peripheral T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ conversion makes it the thionamide of choice.

Severe Methimazole Allergy : When radioiodine or surgery is delayed.

Critical Adverse Effects of Thionamides :

Agranulocytosis (absolute neutrophil count [ANC] <500/mcL): Occurs in 0.2% to 0.5% of patients, typically within the first 90 days of therapy. Idiosyncratic, immune-mediated destruction of myeloid precursors. Mandatory Patient Warning : Educate every patient to immediately stop taking the medication and obtain a stat Complete Blood Count (CBC) with differential if they develop a fever, sore throat (pharyngitis), mouth sores, or signs of infection ! Routine serial CBC monitoring without symptoms is not cost-effective.

Hepatotoxicity : PTU carries an FDA Black Box warning for fulminant hepatic necrosis leading to acute liver failure, transplantation, or death. Methimazole typically causes cholestatic jaundice rather than hepatocellular necrosis.

Minor reactions: Pruritic maculopapular rash, urticaria, arthralgias (5% of patients; managed with antihistamines without stopping therapy unless severe).

Radioactive Iodine ( 131 I ^{131}\text{I} 131 I ) Ablation :

Administered orally as a single sodium iodide-131 capsule. Beta particles destroy follicular cells over 6 to 18 weeks, inducing permanent hypothyroidism in >80% to 90% of patients.

Absolute Contraindications : Pregnancy and breastfeeding (RAI concentrates in fetal/neonatal thyroid, causing cretinism).

Relative Contraindication: Moderate-to-Severe Active Graves Orbitopathy : Radioactive iodine ablation causes cell lysis, releasing large quantities of thyroid antigens into circulation, which can trigger an autoimmune flare that dramatically worsens exophthalmos and retro-orbital fibrosis. If RAI is administered to patients with mild orbitopathy, concurrent oral prednisone prophylaxis (0.3 to 0.5 mg/kg/day tapered over 3 months) is mandatory.

Total or Near-Total Thyroidectomy :

Indications : Obstructive compressive symptoms (dysphagia, stridor, retrosternal extension); coexisting suspicious or malignant thyroid nodule; moderate-to-severe active Graves ophthalmopathy; pregnancy when antithyroid medications are contraindicated or toxic; or patient preference against radioiodine.

Preoperative Preparation : Must achieve euthyroidism preoperatively using antithyroid drugs plus saturated solution of potassium iodide ( SSKI or Lugol solution ) given 7 to 10 days preoperatively to decrease thyroid gland vascularity and intraoperative hemorrhage.

Surgical Complications : Postoperative hypocalcemia from transient or permanent hypoparathyroidism (check ionized calcium/PTH post-op) and recurrent laryngeal nerve palsy (hoarseness).

Subacute Granulomatous (De Quervain) Thyroiditis

Self-limiting inflammatory condition typically following a viral upper respiratory infection (Coxsackievirus, adenovirus, mumps, echovirus).

Hallmark Features : Exquisitely painful and tender enlarged thyroid gland , with severe neck pain radiating to the jaw, ears, or occiput, accompanied by low-grade fever and malaise.

Laboratory Profile : Markedly elevated erythrocyte sedimentation rate ( ESR often >60 to 100 mm/hr ) and high C-reactive protein (CRP). Thyroid hormone levels exhibit a triphasic clinical course: transient thyrotoxicosis (4-6 weeks) -> transient hypothyroidism (weeks to months) -> complete euthyroid recovery (>90% of cases).

Treatment Protocol : Antithyroid drugs (methimazole, PTU) are completely contraindicated and ineffective because thyrotoxicosis is caused by follicular leakage of preformed colloid, not new synthesis. High-dose NSAIDs (ibuprofen 600-800 mg three times daily) are first-line for mild-to-moderate pain. For severe pain or refractory cases, initiate oral prednisone (40 mg daily tapered over 4 to 6 weeks) . Beta-blockers (propranolol) manage adrenergic thyrotoxic symptoms.

Acute Thyroid Storm: The 5-Drug Resuscitation Bundle

Thyroid storm is a catastrophic, life-threatening hypermetabolic emergency characterized by decompensated multi-organ failure, carrying a mortality rate of 10% to 30%. Diagnosed clinically using the Burch-Wartofsky Point Scale (score >=45 highly suggestive) .

Clinical Hallmarks : Hyperpyrexia (fever 104°F to 106°F [40°C-41°C]), marked sinus tachycardia (>140 bpm), atrial fibrillation, congestive heart failure, profuse diaphoresis, severe agitation, delirium, frank psychosis, diarrhea, nausea, and jaundice.

The Immediate 5-Drug Resuscitation Sequence :

Step 1: Beta-Blocker : Propranolol 60 to 80 mg PO every 4 hours (or IV esmolol infusion) to block peripheral sympathetic storm and inhibit T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ conversion.

Step 2: Antithyroid Drug : Propylthiouracil (PTU) 500 to 1,000 mg loading dose PO/rectal, followed by 250 mg every 4 hours to halt new hormone synthesis.

Step 3: Inorganic Iodine (Lugol Solution or SSKI) : Administer Lugol solution (10 drops TID) or SSKI (5 drops q6h) STRICTLY AT LEAST 1 HOUR AFTER THE INITIAL PTU DOSE ! Administering iodine before blocking the gland allows the thyroid to utilize the exogenous iodine as substrate for accelerated de novo hormone synthesis (the Jod-Basedow phenomenon), worsening thyrotoxicosis. When given after PTU, high-dose iodine acutely inhibits thyroid hormone release (the Wolff-Chaikoff effect).

Step 4: High-Dose Glucocorticoids : Hydrocortisone 100 mg IV every 8 hours (or dexamethasone 2 mg q6h) to reduce peripheral T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ conversion and protect against relative adrenal exhaustion.

Step 5: Supportive Cooling & Bile Acid Sequestrants : Acetaminophen for fever ( avoid aspirin / NSAIDs , which displace T 4 T_4 T 4 ​ and T 3 T_3 T 3 ​ from thyroxine-binding globulin, elevating free hormone levels!); active external cooling blankets; cholestyramine 4 g PO QID to bind thyroid hormones in the gut lumen and interrupt enterohepatic recirculation.

Thyroid Nodules: ATA Evaluation Guidelines, TI-RADS & Bethesda Cytopathology

Thyroid nodules are exceptionally common in clinical practice, identifiable by high-resolution ultrasonography in up to 50% to 60% of asymptomatic adults. The primary clinical imperative is excluding thyroid carcinoma, which occurs in approximately 7% to 15% of evaluated nodules.

American Thyroid Association (ATA) Stepwise Evaluation Protocol ATA THYROID NODULE INITIAL DIAGNOSTIC PROTOCOL

• Palpable Thyroid Nodule OR Incidentaloma Detected on Imaging (CT, MRI, PET)
• │
• ▼
• Measure Serum TSH + Dedicated Thyroid Ultrasound
• │
• ┌──────────────────┴──────────────────┐
• ▼ ▼
• Serum TSH is SUPPRESSED Serum TSH is NORMAL or ELEVATED
• │ │
• ▼ ▼
• Radionuclide Thyroid Scan Dedicated Neck Ultrasonography
• (I-123 or Tc-99m Scintigraphy) (Stratify by ACR TI-RADS Criteria)
• │ │
• ┌────────┴────────┐ ▼
• ▼ ▼ Determine Need for Fine-Needle
• "HOT" Nodule "COLD" Nodule Aspiration (FNA) Biopsy
• (Autonomous) (Non-functioning) Based on TI-RADS Score & Size
• │ │
• NO BIOPSY! Proceed to
• Treat Hyperthy Ultrasound-Guided
• (Surgery/RAI) FNA per TI-RADS

Step 1: Serum TSH Measurement :

If serum TSH is suppressed (< normal) , the patient has hyperthyroidism or autonomous nodular function. The next mandatory diagnostic step is a radionuclide thyroid scan (using Iodine-123 or Technetium-99m) .

Hot (Hyperfunctioning) Nodule : Accumulates radiotracer with suppression of surrounding extranodular tissue. Hot nodules are virtually never malignant (<1% cancer risk) and do NOT require fine-needle aspiration (FNA) biopsy ! Manage medically or with radioiodine ablation.

Cold (Non-functioning) Nodule : Shows decreased or absent radiotracer uptake compared to normal parenchyma. Carries an ~8% to 15% malignancy risk; proceed to dedicated neck ultrasound and biopsy evaluation.

If serum TSH is normal or elevated , a radionuclide scan is completely uninformative. The patient requires a dedicated high-resolution neck ultrasound to evaluate nodule morphology and cervical lymph node stations.

ACR TI-RADS: Ultrasound Risk Stratification & Biopsy Criteria

The American College of Radiology Thyroid Imaging, Reporting and Data System (ACR TI-RADS) standardizes ultrasound risk stratification. Points are assigned across 5 ultrasound categories, generating a cumulative score that dictates whether FNA or serial surveillance is required: ACR TI-RADS SCORING CATEGORIES & POINTS

• Category Ultrasound Features & Assigned Points
• ═════════════════════════════════════════════════════════════════════════════
• Composition Cystic or completely cystic (0 pts) | Spongiform (0 pts)
• Mixed cystic and solid (1 pt) | Solid or almost completely solid (2 pts)

• Echogenicity Anechoic (0 pts) | Hyperechoic or isoechoic (1 pt)
• Hypoechoic (2 pts) | Very hypoechoic (3 pts)

Shape Wider-than-tall (0 pts) | Taller-than-wide (AP > Transverse) (3 pts)

• Margin Smooth (0 pts) | Ill-defined (0 pts)
• Lobulated or irregular (2 pts) | Extra-thyroidal extension (3 pts)

• Echogenic Foci None or large comet-tail artifacts (0 pts)
• Macrocalcifications (1 pt) | Peripheral (rim) calcifications (2 pts)
• Punctate echogenic foci (microcalcifications) (3 pts)

═════════════════════════════════════════════════════════════════════════════ ACR TI-RADS CLASSIFICATION & FNA SIZE CUTOFFS

• TI-RADS Level Suspicion Level Total Points FNA Biopsy Threshold Follow-Up US Threshold
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• TR1 Benign 0 points No FNA No follow-up
• TR2 Not Suspicious 2 points No FNA No follow-up
• TR3 Mildly Suspicious 3 points Biopsy if >= 2.5 cm Follow if >= 1.5 cm
• TR4 Moderately Suspicious 4 to 6 points Biopsy if >= 1.5 cm Follow if >= 1.0 cm
• TR5 Highly Suspicious >= 7 points Biopsy if >= 1.0 cm Follow if >= 0.5 cm
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• *Any nodule presenting with suspicious cervical lymphadenopathy warrants immediate biopsy of the lymph node

and thyroid nodule regardless of TI-RADS points or size.

The Bethesda System for Reporting Thyroid Cytopathology

Fine-needle aspiration (FNA) cytology is interpreted according to the internationally standardized Bethesda System , which guides oncologic risk stratification and surgical decision-making: THE BETHESDA SYSTEM FOR THYROID CYTOPATHOLOGY

• Bethesda Class Diagnostic Category Malignancy Risk Clinical Management Strategy
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Bethesda I Nondiagnostic or Unsatisfactory 1% to 4% Repeat ultrasound-guided FNA in
• (insufficient follicular cells, cyst) 6 to 12 weeks

• Bethesda II Benign 0% to 3% Clinical & ultrasound surveillance
• (colloid nodule, lymphocytic thyroiditis) at 12 to 24 months; no surgery

• Bethesda III Atypia of Undetermined Significance 10% to 30% Molecular testing (ThyroSeq/Afirma)
• (AUS) or Follicular Lesion (FLUS) OR repeat FNA in 3 months

• Bethesda IV Follicular Neoplasm or Suspicious 25% to 40% Molecular testing OR diagnostic
• for Follicular Neoplasm (FN/SFN) surgical lobectomy (hemithyroidectomy)

• Bethesda V Suspicious for Malignancy 60% to 75% Surgical resection: thyroid lobectomy
• (features concerning for papillary cancer) or total thyroidectomy

Bethesda VI Malignant 97% to 99% Definitive oncologic surgery:

• (frank papillary, medullary, anaplastic) total thyroidectomy ± neck dissection
• ═════════════════════════════════════════════════════════════════════════════

Pathology Nuance for Bethesda IV (Follicular Neoplasms) :

Cytopathology from an FNA cannot distinguish a benign follicular adenoma from a malignant follicular thyroid carcinoma . The cytological appearance of follicular cells is identical in both.

The definitive histopathologic hallmark distinguishing follicular carcinoma is the demonstration of capsular invasion or vascular invasion through the tumor capsule, which requires full histologic sectioning of the resected surgical specimen. Therefore, surgical lobectomy or validated molecular testing is required.

Thyroid Malignancies: Clinical & Pathologic Hallmarks

Papillary Thyroid Carcinoma (PTC) :

Most common thyroid malignancy (80% to 85% of all cases); 3:1 female predilection; associated with prior childhood ionizing radiation exposure.

Prognosis : Excellent (>95% to 98% 10-year survival rate).

Pathologic Hallmarks : Spreads predominantly via lymphatics to regional cervical lymph nodes . Characteristic microscopic cytological features:

• Enlarged, overlapping, clear ground-glass nuclei ( "Orphan Annie eye" nuclei )
• Longitudinal nuclear grooves and intranuclear cytoplasmic pseudo-inclusions

Psammoma bodies : Concentrically laminated, basophilic calcospherites (calcified necrotic papillae tips).

Follicular Thyroid Carcinoma (FTC) :

Second most common (10% to 15% of cases); more prevalent in iodine-deficient areas.

Spread Pattern : Spreads hematogenously (via blood vessels) to distant bones and lungs; regional lymph node involvement is rare (<10%). Excellent overall prognosis (~85% to 90% 10-year survival).

Medullary Thyroid Carcinoma (MTC) :

Arises from neuroendocrine parafollicular C-cells that synthesize calcitonin (accounts for 3% to 5% of thyroid cancers).

Familial Association : 25% of cases are hereditary, driven by germline activating mutations in the RET proto-oncogene as a component of Multiple Endocrine Neoplasia Type 2 (MEN 2A and MEN 2B) or Familial MTC.

Clinical Biomarkers : Serum calcitonin (diagnostic marker and tumor burden monitor) and carcinoembryonic antigen (CEA) .

MANDATORY BOARD EXAM RULE : Before undertaking thyroid surgery in a patient diagnosed with medullary thyroid carcinoma, the clinician must always screen for a coexisting pheochromocytoma (measure plasma free metanephrines or 24-hour urine metanephrines)! Overlooking an occult pheochromocytoma can trigger fatal intraoperative hypertensive crisis during anesthesia induction.

Anaplastic (Undifferentiated) Thyroid Carcinoma :

Accounts for 1% to 2% of thyroid cancers, occurring predominantly in elderly patients (>=65 years).

Clinical Presentation : Catastrophically aggressive, rapidly enlarging, rock-hard anterior neck mass that infiltrates surrounding cervical structures within weeks, presenting with acute hoarseness, stridor, dyspnea, and dysphagia.

Prognosis : Dreadful (median survival 3 to 6 months). Highly resistant to radioiodine, surgical cure, and conventional chemotherapy. Management focuses on securing the airway (tracheostomy) and palliative targeted therapies.

Loading diagram... Clinical Algorithm for Thyroid Functional Staging, Nodule Evaluation & Biopsy Stratification